Pharma On Its Back Foot As US Drug Price Reform Advances
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.
You may also be interested in...
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.
"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke about competitive rebating and new growth opportunities for anchor brands.